Plevitrexed is primarily used in the field of oncology as an anticancer agent. It functions as a thymidylate synthase inhibitor, which plays a crucial role in DNA synthesis and repair. By inhibiting this enzyme, Plevitrexed effectively disrupts the proliferation of cancer cells, particularly in solid tumors. It has been studied for its potential in treating various cancers, including colorectal, pancreatic, and non-small cell lung cancer. The drug is often explored in combination with other chemotherapeutic agents to enhance its efficacy and reduce resistance. Its targeted mechanism of action makes it a promising candidate for personalized cancer therapy, especially in cases where traditional treatments have limited success.